Robert is a corporate lawyer advising clients on transactional, corporate governance and disclosure matters. His practice is broad-based, with particular emphasis on the representation of public companies in the life sciences sector.
His transactional practice focuses on mergers and acquisitions and strategic alliances structured to advance innovative technologies.
Working with management teams and boards of directors, Robert also advises on corporate governance policies, as well as matters relating to activist defense.
Robert advises clients on public disclosures regarding a range of important corporate developments.
Education
-
New York University School of Law, J.D.
-
Columbia University, Columbia College, B.A.
Admissions & Qualifications
- New York
Memberships
New York Biotechnology Association
Awards & Recognition
The Legal 500 United States: Mergers, Acquisitions and Buyouts: Large Deals 2018
The Legal 500 United States: Finance: Capital Markets: Debt Offerings 2015, 2018
The Legal 500 United States: Healthcare: Life Sciences 2013-2014, 2020-2023
Best Lawyers in America 2008-2016, 2018-2023
New York Super Lawyers 2006, 2013-2015, 2017-2020
Matters
Illustrative client matters include:
- $9.0 billion acquisition of Juno Therapeutics, Inc.
- $7.2 billion acquisition of Receptos, Inc.
- $2.9 billion acquisition of Pharmion Corporation
- $1.9 billion sale of Andrx Corporation
- $600 million acquisition of EngMab AG
- $300 million acquisition of Delinia, Inc.
- Acquisition of pharmaceutical product portfolio from Novartis Pharma AG by Mereo BioPharma Group Ltd
- Acquisition of product rights by Braeburn Pharmaceuticals
- Strategic investments, collaborations and options to acquire involving:
- Acetylon Pharmaceuticals, Inc.
- Alliqua BioMedical
- Crispr Therapeutics AG
- EngMab AG
- Human Longevity, Inc.
- Inception IBD, Inc.
- Lycera Corp.
- Nimbus Therapeutics, Inc.
- Northern Biologics Inc.
- Skyhawk Therapeutics, Inc.
- VAXON Biotech SA
- VentiRx Pharmaceuticals